Salud financiera de hoja de balance de ANI Pharmaceuticals
Salud financiera controles de criterios 5/6
ANI Pharmaceuticals tiene un patrimonio de accionistas total de $480.6M y una deuda total de $285.2M, lo que sitúa su ratio deuda-patrimonio en 59.4%. Sus activos y pasivos totales son $920.8M y $440.1M respectivamente. El BAIT de ANI Pharmaceuticals es de $48.2M, por lo que su ratio de cobertura de intereses es de 2.3. Tiene efectivo e inversiones a corto plazo que ascienden a $247.1M.
Información clave
59.4%
Ratio deuda-patrimonio
US$285.24m
Deuda
| Ratio de cobertura de intereses | 2.3x |
| Efectivo | US$247.05m |
| Patrimonio | US$480.61m |
| Total pasivo | US$440.14m |
| Activos totales | US$920.75m |
Actualizaciones recientes sobre salud financiera
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08
These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28Recent updates
ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Nov 02ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Oct 11There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28ANI Pharma launches generic Prochlorperazine maleate tablets
Aug 29ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval
Aug 16ANI Pharmaceuticals Q2 2022 Earnings Preview
Aug 05Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($555.5M) de ANIP superan a sus pasivos a corto plazo ($140.0M).
Pasivo a largo plazo: Los activos a corto plazo de ANIP ($555.5M) superan a sus pasivos a largo plazo ($300.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (7.9%) de ANIP se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de ANIP ha pasado de 92.5% a 59.4% en los últimos 5 años.
Cobertura de la deuda: La deuda de ANIP está bien cubierta por el flujo de caja operativo (39.5%).
Cobertura de intereses: Los pagos de intereses de la deuda de ANIP no están bien cubiertos por el BAIT (2.3x cobertura).